Lv4
790 积分 2023-09-07 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
14天前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
15天前
已关闭
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
15天前
已完结
Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer
1个月前
已完结
HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
1个月前
已完结
Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins
1个月前
已完结
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
1个月前
已完结
Peripheral T-cell lymphoma: Are all patients high-risk?
1个月前
已关闭
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2个月前
已完结
Elucidating the Role of EGFR L858R in Brain Metastasis Among Patients with Advanced NSCLC Undergoing TKI Therapy
3个月前
已完结
皖公网安备34019202002308
